key: cord-0774285-swtyqjm7
authors: Blain, Hubert; Tuaillon, Edouard; Gamon, Lucie; Pisoni, Amandine; Miot, Stéphanie; Rolland, Yves; Picot, Marie‐Christine; Bousquet, Jean
title: Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study
date: 2021-07-29
journal: Allergy
DOI: 10.1111/all.15007
sha: bd8dfbf34ef8b7171fe57ef147c48e0fb94335df
doc_id: 774285
cord_uid: swtyqjm7

BACKGROUND: The humoral immune response following COVID‐19 vaccination in nursing home residents is poorly known. A longitudinal study compared levels of IgG antibodies against the spike protein (S‐RBD IgG) (S‐RDB protein IgG) after one and two BNT162b2/Pfizer jabs in residents with and without prior COVID‐19. METHODS: In 22 French nursing homes, COVID‐19 was diagnosed with real‐time reverse‐transcriptase polymerase chain reaction (RT‐PCR) for SARS‐CoV‐2. Blood S‐RDB‐protein IgG and nucleocapsid (N) IgG protein (N‐protein IgG) were measured 21–24 days after the first jab (1,004 residents) and 6 weeks after the second (820 residents). RESULTS: In 735 residents without prior COVID‐19, 41.7% remained seronegative for S‐RDB‐protein IgG after the first jab vs. 2.1% of the 270 RT‐PCR‐positive residents (p < 0.001). After the second jab, 3% of the 586 residents without prior COVID‐19 remained seronegative. However, 26.5% had low S‐RDB‐protein IgG levels (50–1050 UA/ml) vs. 6.4% of the 222 residents with prior COVID‐19. Residents with an older infection (first wave), or with N‐protein IgG at the time of vaccination, had the highest S‐RDB‐protein IgG levels. Residents with a prior COVID‐19 infection had higher S‐RDB‐protein IgG levels after one jab than those without after two jabs. INTERPRETATION: A single vaccine jab is sufficient to reach a high humoral immune response in residents with prior COVID‐19. Most residents without prior COVID‐19 are seropositive for S‐RDB‐protein IgG after the second jab, but around 30% have low levels. Whether residents with no or low post‐vaccine S‐RDB protein IgG are at higher risk of symptomatic COVID‐19 requires further analysis.

Nursing home (NH) residents are at high risk of serious illness and death from COVID-19 due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 1 In NHs facing a COVID-19 outbreak, infection prevention and control (IPC) measures based on results of repeated testing by real-time reverse-transcriptase polymerase chain reaction for SARS-CoV-2 (RT-PCR) in all residents can limit coronavirus transmission. 2, 3 Residents with prior COVID-19 may be protected against reinfection during outbreaks in NHs. 4 Vaccination against SARS-CoV-2 is safe and effective in preventing COVID-19 in adults, 5 and immunocompetent SARS-CoV-2-seropositive adults might only require one jab of the Pfizer-BioNTech or the Moderna mRNA vaccines to reach immunity. 6, 7 Age or immune dysregulation may impact immune response to COVID-19 vaccination. The level of N-protein IgG produced after SARS-CoV-2 infection, associated with a substantially reduced risk of SARS-CoV-2 reinfection, 8 declines over time. 9 In the Danish Microbiology Database, protection against reinfection was found to be reduced in participants over 65 years. 10 Age seems also to reduce serological response after vaccination of kidney 11 or liver transplant recipients, 12 and of patients with chronic lymphocytic leukemia, 13 cancer, 14 or hemodialysis. 15 Few data exist on post-vaccine immunity in NH residents, and the size of the study is usually low. After one jab, binding antibodies against S-RDB-protein were approximately fourfold lower in residents compared with healthcare professionals. 16, 17 Although the increment of antibody levels after the second immunisation may be higher in older participants, the absolute mean titer of this group seems to remain lower in NH residents aged over 80 years than in those under 60. 18 A pilot study showed that NH residents having had in the past 9-12 months had much higher levels of antibodies against the SARS-CoV-2 S-RDB-protein (S-RDB-protein IgG) after a single BNT162b2 jab than residents not having had COVID-19. 16 It remains therefore necessary (a) to confirm in a large sample of residents whether the S-protein IgG response after a single BNT162b2 jab may be influenced by prior COVID-19 infection, (b) to determine in former COVID-19 residents whether the S-protein IgG response after a single BNT162b2 jab may be influenced by the time elapsed since the COVID-19 infection and by the persistence of a natural immunity against N-protein, and (c) to assess the S-protein IgG response after the second vaccination in residents with vs. without prior COVID-19.

We first compared S-and N-protein IgG levels 3 weeks after a single BNT162b2 jab in a large group of residents with vs. without prior COVID-19 confirmed by RT-PCR (RT-PCR-positive residents). Two periods were considered-the past 9 to 12 months (older infections) and the past 3 to 7 months (newer infections)-corresponding to the first and second waves of the epidemic in our region (March-June 2020 and September-December 2020). Secondly, we assessed the S-protein IgG response in these residents 6 weeks after the second vaccination.

A longitudinal study was carried out on NHs having faced a COVID-19 outbreak in 2020. First, we compared N-and S-protein IgG levels three weeks after a single BNT162b2 jab in residents

This study compares levels of IgG antibodies against the spike protein (S-RBD IgG) (S-RDB protein IgG) after one and two BNT162b2/ Pfizer jabs in residents with and without prior COVID-19. One BNT162b2 jab is sufficient to reach an S-RBD protein IgG level of 1050 AU/ ml in 98% of nursing home residents with prior COVID-19. After two jabs, levels of S-RBD IgG are below 1050 AU/ml in 29.5% of residents without prior COVID-19. Abbreviations: AU/ml, arbitrary units per ml; COVID-19, coronavirus disease 2019; RT-PCR, real-time reversetranscriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S-RBD IgG, IgG antibodies against the spike protein.

without prior COVID-19 (with repeated negative RT-PCR and negative N-protein IgG measured 3 weeks after the jab) vs. residents with prior COVID-19 (confirmed either by a positive RT-PCR or by detectable N-protein IgG). Two periods were considered-the past 9 to 12 months (older infections) and the past 3 to 7 months (newer infections)-corresponding to the first and second waves of the epidemic in our region.

Second, S-protein levels were compared six weeks after a second BNT162b2 jab in residents with vs. without prior COVID-19.

We included 22 NHs of the Montpellier area (France), each with at least five residents with a previous diagnosis of COVID-19 confirmed by RT-PCR on a nasopharyngeal swab test between March and December 2020 (PCR-positive residents). This study follows previous studies conducted in the same NHs with a COVID-19 outbreak between March and June 2020. 16, 19, 20 

As previously reported, 16, 19, 20 as soon as a resident developed COVID-19 in a NH, all residents and staff members were repeatedly tested using RT-PCR on nasopharyngeal swab until no new cases were diagnosed. This was the procedure recommended by the Health Agency of our region, in accordance with the European Geriatric Medicine Society guidance. 3 Comorbidities were assessed according to a previous paper. 2 The same population was studied during the first COVID-19 wave.

All residents who had not had COVID-19 in the last 3 months, and who signed an informed consent, were offered the first jab of the We used a control group of younger healthcare workers to assess the differences with NH residents who had never had a positive RT-PCR and who had undetectable N-protein IgG levels after vaccination.

S-RDB-protein IgG against the SARS-CoV-2 receptor-binding domain (RBD) of the S1 subunit was detected using the SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics). Results were expressed as arbitrary units per ml (AU/ml; positive threshold: 50 AU/ml; upper limit: 40,000 AU/ml; a level ≥1,050 AU/ml was considered as a significant response 21 and a level ≥4160 AU/ml indicated a high neutralising effect according to the manufacturer). N-protein IgG was detected using the SARS-CoV-2 IgG assay (Abbott Diagnostics). Results were expressed as a signal to cutoff ratio (S/CO; Abbott Alinity; positive threshold: 0.8 S/CO). 22 The humoral immune response was first assessed 3 weeks after the first jab, i.e. just before the second one. The boost induces a second wave, generating longer-lived plasma cells that provide long-lived immunity, but a waning of antibodies during the first. This is why it is necessary to study the S-RBD protein level 6 weeks after the second jab. 23 

The sample size was not calculated since we aimed to study all possible NH residents.

Qualitative variables were described with frequency and proportions for each category. The description of quantitative variables was performed using mean and standard deviation and/or median, minimum, and maximum values. N-protein and S-RBD-protein IgG levels were compared in residents (a) with and without prior COVID-19, (b) with prior COVID-19 during the first or second wave of the epidemic, and (c) who remained or did not remain seropositive for Nprotein IgG. Wilcoxon-Mann-Whitney two-sided tests were used, qualitative variables were compared using a chi-square test, and the statistical significance threshold was set at 5%. Analyses were performed using the SAS Enterprise Guide, v7.3 (SAS Institute Inc.).

Among the 1,243 eligible residents, 1,004 were analysed to assess the antibody response after the first jab. Seven hundred and thirtyfive residents had always tested negative for SARS-CoV-2 RNA by RT-PCR, 94 had tested positive 9 to 12 months before the vaccine, and 176 had tested positive 3 to 7 months before. Among those 1,004 residents, 808 accepted the second jab and agreed to participate in the study ( Figure 1 ). Most residents were females.

N-protein IgG were detectable (≥ 0.8 signal to cutoff ratio) in 42 (5.7%) of the 735 negative RT-PCR residents. These residents were then considered as having a prior infection by SARS-CoV-2.

Residents with an older infection were less frequently seropositive for N-protein IgG than residents with a newer infection (61.1% vs.

83.7%, p < .001) ( Table 1 ). The N-protein IgG median level was lower in residents with an older infection than in those with a newer infection (p < 0.001). Corresponds to residents with negative RT-PCR in the last 12 months and with positive N-Protein IgG.

c Corresponds to residents with posittive RT-PCR in the last 9-12 months.

d Corresponds to residents with positive RT-PCR in the 3 to 7 months ago. Comorbidities were studied in 433 residents during the first wave (94.9% were tested). We found no significant link between comorbidities and S-RBD-protein IgG levels after the first or second jab, in the residents with or without prior COVID-19 (Tables S1-S4 ).

In the 181 positive PCR residents of the first wave, 40% were asymptomatic. Asymptomatic residents had non-significantly different S-protein IgG levels 6 weeks after the second jab when compared to symptomatic residents (Fisher's test = 0.27, Table S5 ).

Among the RT-PCR-positive residents, the median levels of S-RBD-protein IgG after vaccine were ranked in the following order: 

Six weeks after the second BNT162b2 jab, only around 3% of the 554 residents without prior COVID-19 had undetectable S-RBDprotein IgG levels (<50 AU/ml) vs. none of the residents with a prior positive PCR (Table 3 ). The prevalence of residents with low S-RBDprotein IgG levels (≤1,050 AU/ml) was significantly lower in residents without prior COVID-19 than in those with a positive PCR in the last 3 to 12 months (28.3% vs. 2.7%, p < 0.001). The median value of S-RBD-protein IgG in residents without prior COVID-19 after two jabs was 10-fold lower than that in residents with prior COVID-19 after one jab (2,384 AU/ml vs. 23,259 AU/ml).

Recent studies conducted in small samples of immunocompetent adults showed higher levels of S-RBD-protein IgG after a single jab in individuals with prior COVID-19 than in those without prior COVID-19. 5, 24 Our pilot study with 136 residents is the only one to have included NH residents. 16 The current study is innovative 

Three weeks after a single jab of BNT162b2 vaccine, residents with an older infection were less often seropositive for N-protein IgG than It is reassuring to note that 80% of the RT-PCR-positive residents with an older infection but who do not have a persistent humoral immunity exhibit a high S-RBD-protein IgG level after the vaccine.

This result suggests a long-term persistence of previously-generated memory B cells that can induce a rapid clonal expansion and terminal differentiation to produce high-affinity anti-S-RBD-protein IgG after the vaccine, 32 as observed for common viruses. 33 In line with this hypothesis, a robust boosting after the first mRNA jab was found to strongly correlate with levels of pre-existing memory B cells in recovered individuals, identifying a key role for memory B cells in recall responses to SARS-CoV-2 antigens. 34 Taken together, these results suggest that both natural humoral immunity (that appears to decrease over time) and cellular immunity (that seems to be main- The present study shows that NH residents with prior COVID-19

achieve much higher S-RBD-protein IgG levels after one single jab than in younger COVID-19 convalescents. 36 It remains to be determined whether vaccinated residents with prior COVID-19 (with at least one jab) will be better protected against reinfection during outbreaks in NHs than unvaccinated residents with prior COVID-19. 4

The persistence of N-protein IgG in 85.7% of residents with a newer infection (in the past 3 to 7 months) and the increase in S-RBDprotein level observed with increasing time between COVID-19 and vaccination both support the hypothesis that, in most residents, the vaccine should be administered at least 3 months after COVID-19

infection, even if reinfection is possible within those 3 months. 37 

Although this study has been carried out in one European region, its size allows generalisability in residents infected by the natural strain of the virus. New studies are needed to study the post-vaccine antibody response in residents infected by different variants. This present study supports the hypothesis that (a) Most of the residents having recovered from COVID-19 (with a diagnosis using RT-PCR or N-protein IgG) may only require one single jab to achieve peak antibody and memory B cell responses. (b) The second jab reduces however the prevalence of residents with low S-RBD-protein IgG levels (≤1050 AU/ml) (from 11.5% to 2.7%). (c)

For individuals whose infection history is unknown, measuring S-RBD-protein IgG antibody levels just before the second jab could be useful in determining whether a second jab is required. material support, as well as (iii) the residents and staff members of the nursing homes involved in the study. None of these contributors received any compensation for their help in carrying out the study.

The authors declare no conflicts of interest/competing interests.

Jean Bousquet https://orcid.org/0000-0002-4061-4766

Epidemiology of covid-19 in a long-term care facility in king county, Washington

Efficacy of a test-retest strategy in residents and health care personnel of a nursing home facing a COVID-19 outbreak

Interim EuGMS guidance to prepare European long-term care facilities for COVID-19

Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes

Safety and efficacy of the BNT162b2 mRNA covid-19 Vaccine

Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Antibody status and incidence of SARS-CoV-2 infection in health care workers

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Impaired Humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors

Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis

Spike Antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose

Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine. medRxiv

Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination

Atypical clinical presentation of COVID-19 infection in residents of a long-term care facility

Atypical symptoms, SARS-CoV-2 test results, and immunization rates in 456 residents from eight nursing homes facing a COVID-19 outbreak

Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in nursing home residents

Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients

The power of antibody-based surveillance

Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection

SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline

Durability of SARS-CoV-2 IgG antibody among residents in a longterm care community

Rapid Decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Preexisting immunity, more than aging, influences influenza vaccine responses

Preexisting immunity, not frailty phenotype, predicts influenza postvaccination titers among older veterans

Evolution of antibody immunity to SARS-CoV-2

Duration of humoral immunity to common viral and vaccine antigens

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination

Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients

Genomic evidence for reinfection with SARS-CoV-2: a case study

Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptorbinding domain IgG correlate with virus neutralization

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

COVID-19 outbreak associated with a SARS-CoV-2 R.1 lineage variant in a skilled nursing facility after vaccination program-Kentucky

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2

BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant viruses is up to 10-fold reduced